Menu
Search
Subscribe to Snippets
Obviousness of Pharmaceuticals – Patentability Over Known, Structurally Similar Compounds
Article co-written by Yuri Levin-Schwartz, Ph.D., a law clerk at MBHB.
Sherri L. Oslick
Private: Bradley W. Crawford
Spring 2011 (snippets)
Snippets
Practices & Technologies
Trade Secrets
Counseling
Litigation & Appeals
Prosecution
Patent
Trademark, Unfair Competition, Advertising Law & Copyright
Biotechnology & Pharmaceuticals
Chemical
Software & Business Methods
Electrical
Mechanical & Materials
Medical Device & Diagnostics
Telecommunications
Federal Circuit Special Committee Recommends Suspension Of Judge Newman For One Year
How To Use (And Not Use) Large Language Models In Patent Application Drafting
About The author
Sherri L. Oslick
Private: Bradley W. Crawford
© 2023 McDonnell Boehnen Hulbert & Berghoff LLP snippets is a trademark of McDonnell Boehnen Hulbert & Berghoff LLP. All rights reserved. The information contained in this newsletter reflects the understanding and opinions of the author(s) and is provided to you for informational purposes only. It is not intended to and does not represent legal advice. MBHB LLP does not intend to create an attorney–client relationship by providing this information to you. The information in this publication is not a substitute for obtaining legal advice from an attorney licensed in your particular state. snippets may be considered attorney advertising in some states.
Prev
Previous Post
Federal Circuit Defines Joint Tortfeasor Infringement Liability in Akamai v. Limelight
Next Post
What Trademark Owners Need to Know About the New Trademark Rules
Next
Search
Search
Menu
People
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Services
Practices
Technologies
Intelligence
News
Events
Snippets
Patently-O Blog
Patent Docs
Firm
Diversity & Inclusion
Community
Awards & Accolades
Our Clients
Careers
Culture and Development
Career Paths
Diversity, Equity And Inclusion
Legal Professionals
Business Professionals
Locations
Contact Us
Client Pay
Menu